Table 2

Longitudinal analysis of predictors of SDAI, CDAI, DAS28, HAQ-DI and EQ-5D utility values over time using a generalised estimating equation model among postmenopausal patients with RA with a baseline SDAI of >11

Outcome variable	Independent variables	Regression coefficient (β) (95% CI)	P value
SDAI	Age	0.013 (−0.024 to 0.049)	0.503
	RA duration	0.084 (0.046 to 0.122)	<0.001
	Baseline SDAI	0.580 (0.531 to 0.630)	<0.001
	Biologic use	0.196 (−0.924 to 1.315)	0.732
	EM	1.265 (0.412 to 2.117)	0.004
	Follow-up time	−1.806 (−1.964 to −1.647)	<0.001
CDAI	Age	0.013 (−0.022 to 0.047)	0.477
	RA duration	0.086 (0.051 to 0.122)	<0.001
	Baseline CDAI	0.567 (0.518 to 0.617)	<0.001
	Biologic use	0.368 (−0.787 to 1.523)	0.532
	EM	1.208 (0.399 to 2.018)	0.003
	Follow-up time	−1.722 (−1.868 to −1.576)	<0.001
DAS28	Age	0.002 (−0.004 to 0.008)	0.477
	RA duration	0.016 (0.010 to 0.023)	<0.001
	Baseline DAS28	0.613 (0.562 to 0.664)	<0.001
	Biologic use	0.195 (0.022 to 0.369)	0.027
	EM	0.178 (0.038 to 0.319)	0.013
	Follow-up time	−0.315 (−0.340 to −0.290)	<0.001
HAQ-DI	Age	0.007 (0.004 to 0.009)	<0.001
	RA duration	0.011 (0.009 to 0.014)	<0.001
	Baseline HAQ-DI	0.674 (0.638 to 0.711)	<0.001
	Biologic use	0.044 (−0.033 to 0.122)	0.264
	EM	0.092 (0.030 to 0.154)	0.003
	Follow-up time	−0.004 (−0.016 to 0.007)	0.457
EQ-5D utility values	Age	−0.002 (−0.003 to −0.000)	0.007
	RA duration	−0.003 (−0.004 to −0.002)	<0.001
	Baseline EQ-5D utility value	0.532 (0.492 to 0.572)	<0.001
	Biologic use	−0.012 (−0.045 to 0.021)	0.489
	EM	−0.033 (−0.059 to −0.006)	0.016
	Follow-up time	0.010 (0.005 to 0.015)	<0.001

All covariates adjusted in the model were listed as independent variables.
CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score using 28 joint counts; EM, early menopause; EQ-5D, EuroQol-5D; HAQ-DI, Health Assessment Questionnaire–Disability Index; RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index.